Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | YH002 |
| Synonyms | |
| Therapy Description |
YH002 is a humanized agonist OX40 (CD134, TNFRSF4) antibody that activates OX40 downstream signaling, potentially leading to anti-tumor immune response (J Clin Oncol 39, no. 15_suppl, abstract e14501). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| YH002 | YH 002|YH-002 | OX40 Antibody 15 | YH002 is a humanized agonist OX40 (CD134, TNFRSF4) antibody that activates OX40 downstream signaling, potentially leading to anti-tumor immune response (J Clin Oncol 39, no. 15_suppl, abstract e14501). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04353102 | Phase I | YH002 | A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies | Completed | AUS | 0 |